# SPL026 (DMT Fumarate) in Healthy Subjects and MDD Patients

> **NCT04673383** · PHASE1,PHASE2 · COMPLETED · sponsor: **Small Pharma Ltd** · enrollment: 66 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** SPL026
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04673383
- **Lead sponsor:** Small Pharma Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-04
- **Primary completion:** 2022-10-01
- **Final completion:** 2022-12-22
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2024-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04673383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04673383, "SPL026 (DMT Fumarate) in Healthy Subjects and MDD Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04673383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*